Improving Multispecific Antibody Bioprocesses Through Coculture and Column‐Based Redox Reactions: Part II
Biotechnology and Bioengineering · 2025
DOI: 10.1002/bit.28975 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2025. Written by Dawn Eriksen-Stapleton and 16 co-authors. Institution: Pfizer Bioprocess Research and Development, Pfizer, Andover, Massachusetts, USA. Major MEDLINE topics: Bioreactors, Antibodies, Monoclonal. 26 references. Funded by: This work was funded in full by Pfizer..
Abstract (original language)
Multispecifics are increasingly being evaluated in the pharmaceutical industry due to their unique mechanisms of action, enabled by their multiple antigen‐binding capabilities. The complexity of these molecules can make production challenging, prompting the development of various generation approaches. This study employs an electrostatic‐steering generation method, where charge‐based differences between two parental homodimer antibodies drive correct heterodimerization during a redox reaction of the partially purified parental homodimers. This strategy can achieve high conversion to the heterodimer with minimal product‐related impurities. However, it also necessitates separate bioreactors for each parental homodimer, leading to complex manufacturing campaigns. This work introduces a novel bioprocess for electrostatic‐steering‐based multispecifics, combining two unique components. First, two separate cell lines are cocultured, leading to the simultaneous production of both parental homodimers in a single bioreactor. The second component involves a column‐based redox reaction, where the homodimers are captured, and their disulfide bonds are reduced while bound to the protein A resin using a reductant wash. The column is then eluted and neutralized, allowing the reduced parental homodimers to heterodimerize. Finally, the addition of an oxidant enables the reformation of disulfide bonds, completing the formation of the multispecific. This new process is robust and efficient across both the lab bench and manufacturing scales, maintaining well‐controlled impurity profiles. Homodimer harvest ratios were consistently within 10%–15% of the target across various cocultured cell lines. Conversions from homodimers to heterodimers exceeded 90%, and multispecific percentages in all tested drug substance pools were above 95%. This strategy aligns the new multispecific bioprocess with typical antibody‐like processes, optimizing clinical and commercial manufacturing resources while producing complex multispecific molecules with minimal impurities.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Pfizer Bioprocess Research and Development, Pfizer, Andover, Massachusetts, USA.
- Pfizer Biomedicine Design, Pfizer, Andover, Massachusetts, USA.
- Pfizer Analytical Research and Development, Pfizer, Andover, Massachusetts, USA.
ORCID profiles: Dawn Eriksen-Stapleton, Matt Gagnon
Funding
- This work was funded in full by Pfizer.
Cite
APA
Eriksen-Stapleton, D., King, M., Dong, G., Srivastava, D., Iskra, T., Aho, V., Nguyen, K., Ingaharro, L., Scarcelli, J. J., Ochocki, J., Gagnon, M., Hartsough, R., Keo, H., Hulme, C., Coyne, J., Neubauer, C., & Creasy, A. (2025). Improving Multispecific Antibody Bioprocesses Through Coculture and Column‐Based Redox Reactions: Part II. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28975
Vancouver
Eriksen-Stapleton D, King M, Dong G, Srivastava D, Iskra T, Aho V, et al. Improving Multispecific Antibody Bioprocesses Through Coculture and Column‐Based Redox Reactions: Part II. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.28975
BibTeX
@article{EriksenStapleton2025,
author = {Eriksen-Stapleton, Dawn and King, Michael and Dong, Guogang and Srivastava, Dhruv and Iskra, Timothy and Aho, Verzhiniya and Nguyen, Kimberly and Ingaharro, Lia and Scarcelli, John J and Ochocki, Joshua and Gagnon, Matt and Hartsough, Robert and Keo, Hongheng and Hulme, Courtney and Coyne, John and Neubauer, Cassandra and Creasy, Arch},
title = {Improving Multispecific Antibody Bioprocesses Through Coculture and Column‐Based Redox Reactions: Part II},
journal = {Biotechnology and Bioengineering},
year = {2025},
doi = {10.1002/bit.28975}
}
EUVIMED